Compare Charles River Laboratories Intl. Inc (CRL) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Cisco Systems Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Cisco Systems Inc trades at $117.09 (market cap $461.50B). The key difference: Cisco Systems Inc is far larger — about 41.4× Charles River Laboratories Intl. Inc's market cap, and Cisco Systems Inc pays a 1.43% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | CSCO | |
|---|---|---|
Market Cap | $11.14B | $461.50B |
Sector | Health | Technology |
52-Week High | $233.60 | $130.00 |
52-Week Low | $145.57 | $66.20 |
Enterprise Value | $14.00B | $476.17B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Cisco Systems (CSCO) trades at $117.09, down 3.48% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Revenue for 2025 was $56.65 billion, with a net income margin of 19.69%. Recent news highlights Cisco's strategic AI and cybersecurity partnerships, positioning it for growth in the networking and security markets.
The outlook for CSCO is positive, supported by analyst consensus with a $130.38 price target and 52% buy ratings. Key opportunities include AI-driven security demand and solid cash flow. Risks involve competitive pressures and debt levels, with a debt-to-asset ratio of 22.97% in 2025. Investors should weigh strong fundamentals against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
